Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.61 |
| ▸ | POLA1 | P09884 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678866 | 1.00 | NR1H2 (0.61) | NR1H2NR1H3POLA1CYP2C9TSHR | |
| SCHEMBL20561735 | 0.92 | NR1H2 (0.58) | NR1H2NR1H3POLA1CYP2C9TSHR | |
| SCHEMBL21552174 | 0.88 | NR1H2 (0.77) | NR1H2NR1H3POLA1 | |
| SCHEMBL20560970 | 0.83 | NR1H2 (0.87) | NR1H2NR1H3 | |
| SCHEMBL24591986 | 0.83 | NR1H2 (0.69) | NR1H2NR1H3POLA1 | |
| SCHEMBL24270940 | 0.83 | NR1H2 (0.87) | NR1H2NR1H3 | |
| SCHEMBL23962014 | 0.83 | NR1H2 (0.87) | NR1H2NR1H3 | |
| SCHEMBL24591697 | 0.82 | NR1H2 (0.67) | NR1H2NR1H3POLA1 | |
| SCHEMBL24270700 | 0.81 | NR1H2 (0.66) | NR1H2NR1H3CYP2C9TSHRCYP2C19 | |
| SCHEMBL21552124 | 0.81 | NR1H2 (0.66) | NR1H2NR1H3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | NR1H2 3175/4885NR1H3 2873/4885POLA1 3401/4885 |
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | NR1H2 1304/4885NR1H3 1332/4885POLA1 4011/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.